PedsCases: Pediatric Education Online · PedsCases Team

Approach to Childhood Dyslipidemia

April 12, 2024·15 min·1 clip

Catherine Tom reveals how childhood dyslipidemia screening could prevent atherosclerosis starting in kids.

This educational episode from PedsCases provides a clinical approach to childhood dyslipidemia, guided by a Canadian clinical practice update. The host is Catherine Tom, a medical student at McMaster University, and the content is supervised by Dr. Peter Wong, a pediatric cardiologist and author of the practice update. Atherosclerotic processes begin in childhood, and early detection of dyslipidemia is crucial for slowing cardiovascular disease progression. A 2019 survey of 759 Canadian pediatricians found only 3% reported using universal lipid screening, with most screening based on risk factors. The episode defines abnormal lipid levels using thresholds from the 2011 NHLBI expert panel, such as LDL cholesterol greater than or equal to 3.4 mmol/L. Heterozygous familial hypercholesterolemia (FH) is highlighted as the most common single-gene dyslipidemia, increasing risk for premature cardiovascular disease. Obesity-related dyslipidemia is noted as the most common non-genetic cause, with other contributors including diet, medications like corticosteroids, and medical conditions. Universal screening is recommended for children aged 2 to 10 years to improve detection, as selective screening may miss 30-60% of cases. The evaluation of a child with dyslipidemia should include a detailed family history, looking for premature cardiovascular disease in first-degree relatives. Physical exam findings like corneal arcus, tendon xanthomas, and acanthosis nigricans are mentioned as clinical features. A surprising insight is that early statin initiation for children with FH can mitigate cardiovascular risk and promote normal life expectancies. The episode states that genetic testing for dyslipidemia, while helpful for identification and cascade screening, often does not affect current management. Management requires a diagnosis based on the average of at least two fasting lipid profiles taken weeks apart. First-line treatment for all cases involves diet and lifestyle optimization, aligning with Canada's food guide and movement guidelines. Statin therapy can be considered for children aged 8 to 12 with persistently elevated LDL-C, often due to genetic causes, after lifestyle changes. Referral to a pediatric lipid specialist is recommended for marked dyslipidemia, such as LDL-C greater than or equal to 4.5 mmol/L. The tone is instructional and clinical, designed for medical learners. The style is structured, using a case study of a child named Ryan to apply screening and management concepts. This episode is ideal for medical students, pediatric residents, and primary care providers seeking a structured review of pediatric lipid screening guidelines. Listeners looking for debate, patient narratives, or non-clinical perspectives might find it too technical.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from PedsCases: Pediatric Education Online